Prostate Cancer Trials

 


 

Study Title

A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer.

Prinicipal Investigators

Study Number

RTOG 0924

Status of Trial

Open

Why is this study being done?

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.

PURPOSE: This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

NOTE: If you agree to participate in this study, you will receive one of these 2 treatments.

 

Contact

Arla Yost, MSc, CCRP
Email: Arla.Yost@ucsf.edu
Phone: 415-514-9603


Study Title

Phase II Multi-Institutional Trial of Dose Escalated Radiotherapy with Leuprolide and Enzalutamide in Patients with Very High Risk Prostate Cancer

Prinicipal Investigators

Study Number

Enzalutamide-Prostate - 15558

Status of Trial

Open

Why is this study being done?

The purpose of this study is to test the safety of the combination of enzalutamide and leuprolide in patients undergoing standard of care radiation therapy treatment and to determine the response rate of the combination.

Leuprolide is used to treat advanced prostate cancer in men. It is not a cure. Most types of prostate cancer need the testosterone to grow and spread. Leuprolide works by reducing the amount of testosterone that the body makes, but does not completely block the production of testosterone.

Enzalutamide is a drug that can block the binding of testosterone to the receptors on prostate cancer cells. Enzalutamide is approximately 9-fold more effective in blocking testosterone from its receptor when compared to bicalutamide, a drug that is often used in combination with leuprolide. Enzalutamide is approved the US Food and Drug Administration (FDA) for the treatment of metastatic (cancer that has spread) castration-resistant prostate cancer (CRPC). More profound testosterone blockade with the combination of enzalutamide and leuprolide may improve the outcome of patients with very high risk prostate cancer. However, the combination of enzalutamide with leuprolide with radiation therapy (radiotherapy) is considered investigational and has not been approved by the FDA.

Astellas Pharma, the makers of enzalutamide, and the National Comprehensive Cancer Network (NCCN) are providing funding to UCSF to conduct this research trial. UCSF is sponsoring this study.

 

Contact

Arla Yost, MSc, CCRP
Email: Arla.Yost@ucsf.edu
Phone: 415-514-9603


Study Title

Phase I Feasibility Study of Accelerated Hypofractionated Whole Pelvic Radiotherapy for Patients with Intermediate-High Risk Prostate Cancer

Prinicipal Investigators

Study Number

Choline-Prostate - 15551

Status of Trial

Open

Why is this study being done?

This study is being done to see if 11C- and 18F-Choline Positron Emission Tomography/Magnetic Resonance (PET/MR) imaging may help in the characterizing of disease in patients with unfavorable intermediate to high-risk prostate cancer. 11C- and 18F-Choline are radioactive materials, designed for imaging use, and we are testing this agent in this study.

A PET/MR scan produces three dimensional (3-D) images that show the anatomy of the body and how it functions. In order for the PET/MR scanner to take pictures of the body, a small amount of a radioactive material is injected through the vein in the arm. In this study, radioactive 11C- and 18F-Choline will be injected which will allow the study doctors to view areas of suspicious disease within the whole body.

11C- and 18F-Choline is an investigational imaging agent and has not been approved for imaging use by the US Food and Drug Administration (FDA).

General Electric Company and its representatives are providing funding to UCSF to conduct the study

 

Contact

Arla Yost, MSc, CCRP
Email: Arla.Yost@ucsf.edu
Phone: 415-514-9603